Tesamorelin
FDA ApprovedAn FDA-approved GHRH analog specifically approved for reducing excess abdominal fat in HIV patients with lipodystrophy. One of the strongest fat-targeting GH peptides.
Growth HormoneWeight ManagementBody Composition
Half Life
~26 minutes
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyDaily
Cost$$$
🐾 Griffin Says...
One of the few GH peptides with actual FDA approval behind it. The visceral fat reduction data in HIV patients is solid. Researchers are now exploring it for NAFLD (fatty liver disease) too, which is exciting.
Benefits
- Visceral fat reduction
- GH stimulation
- Improved body composition
- Potential liver health benefits (NAFLD research)
Best For
- Visceral fat research
- Body composition
- Metabolic health
Body Systems
EndocrineMetabolicLiver
Mechanisms of Action
- GHRH analog
- Stimulates GH release
- GH reduces visceral adipose tissue
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Joint pain | Common | Mild |
| Water retention | Common | Mild |
| Injection site reactions | Common | Mild |
Contraindications
Active cancer, pregnancy, disruption of hypothalamic-pituitary axis
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator